Daniel Boden, Md Email and Phone Number

Head of Molecular and Cellular Biology leading various research projects pertaining to HIV and HBV cure.Leads several mRNA therapeutic / vaccine preclinical programs.• Directed establishment of a rhinovirus in vivo pharmacology model by in vivo evolution.• Guides assay development and screening / profiling efforts of ASO/siRNAs for immunomodulatory targets.• Provided cross-functional leadership for various programs at Janssen BioPharma, delivering expert guidance on chronic HIV and HBV infection.• Investigated self-amplifying RNA vaccines.• Designed and explored multicistronic Ad26 vectors expressing multiple antigens.• Directed latency reversal agent (LRA) program for HIV cure identifying new LRA [Ref].• Designed and production of rAAV, delivering HBV and NTCP receptor in mice and NHPs.• Evaluated various therapeutic vaccine modalities, resulting in portfolio entry of therapeutic mRNA vaccine for chronic HBV.• Explored CRISP/Cas9 gene editing approaches for HBV cure.• Developed HDV ribozyme reporter screening assay.• Established SELEX aptamer platform for immune checkpoint inhibition.

Group leader of therapeutic HBV vaccine program and directed several checkpoint inhibitor programs. Key responsible to develop innovative molecular assays for HBV antiviral program.• Developed therapeutic DNA vaccine for chronic HBV infection [in Phase 1b].• Developed genetic adjuvant for chronic infections and cancer therapy [patent pending].• Member of the HBV Research Strategy Team and the eCDT.• CRISP/Cas9 engineering of knock-in and knock-out cell lines.• Expert consultant for lentiviral transgene delivery technology.• Established critical assays, identifying new targets for eradication of chronic HBV infection.• Served as internal expert on virology and immunology projects, producing new project proposals and overseeing collaborative research efforts with external partners

Group leader of HIV latency/cure program. Supervised research team including 8 scientists.• Established panel of complex assay systems to screen, identify, and profile candidate hits for HIV cure.• Supervised 700K screening campaign for small molecule latency reversal compounds.• Served as expert in lentiviral and T-cell engineering.• Achieved patent publication of a new molecule with unparalleled activity for HIV eradication.• Directed various external research collaborations.• Coordinated conception and design of innovative screening assay for molecules against respiratory viruses. • 500K library compound screen resulted in promising candidate hits that were further pursued.• Honored with Janssen Research Innovation Award.

Drafted and pursued grants, conceptualized new project opportunities, and led 2 research teams with 10 members. Evaluated and translated team results.• Awarded 3 separate National Institute of Health (NIH) grants, resulting in research that solidified center’s leadership role in HIV MDR research.• Conceptualized and launched programs using commensal bacteria as microbicide against HIV.

Launched virology laboratory operations, prepared grant proposals as well as manuscripts, and sourced international collaborative efforts for research opportunities.• Awarded 2 research grants (AmFAR and CFAR) and named 1st ever group to demonstrate viral escape of HIV-1 to RNA interference using rAAV-2 gene therapy vector delivery.

Oversaw laboratory research operations within clinical virology. Executed implementation of new technologies and assays and drafted proposals for new research opportunities.• Gained experience in clinical and diagnostic virology research with specialization in Hantavirus diagnosis, pathology, and epidemiology.

Developed experience and expertise in HIV-1 virology with particular specialization in drug resistance as well as knowledge regarding molecular virology, biology and immunology. Published multiple peer-reviewed work on HIV-1 drug resistance.

Key role in researching and publishing work in molecular virology with focus on JC virus pathogenesis in HIV-1 infected patients.